Journal of Thrombosis and Thrombolysis

, Volume 28, Issue 2, pp 117–123 | Cite as

A comparison of direct thrombin inhibitors in the treatment of heparin-induced thrombocytopenia: a single institution experience

  • Karen M. Curzio
  • A. Cheng-Lai
  • V. Kheyfets
  • M. Sinnet
  • H. H. Billett
Article

Abstract

Background and objective Heparin-Induced Thrombocytopenia (HIT), if left untreated, can lead to thrombocytopenia, thromboembolic complications and even death. Two thrombin inhibitors, lepirudin and argatroban, have been shown to improve clinical outcomes compared to historical controls in the management of HIT. The purpose of this retrospective study was to compare the effects of lepirudin and argatroban in the management of HIT. Methods Adult subjects with a positive anti-heparin platelet factor 4 (PF4) antibody test and >50% decrease in platelet count during the first 30 days of admission over a period of 2 years were included in the study. Patient demographics, platelet counts, choice of antithrombin therapy, occurrence of thrombosis, length of hospital stay, and date and cause of death, if applicable, were collected for each patient. Results Eighty-two patients met inclusion criteria: 41 patients did not receive any thrombin inhibitors after the diagnosis of HIT, 24 patients received lepirudin and 17 patients received argatroban. Subjects treated with a thrombin inhibitor were more likely to experience platelet count recovery (87.5% for the lepirudin group and 82.4% for the argatroban group) compared to those who did not receive antithrombin therapy (51.2%) after the diagnosis of HIT was made (P < 0.001). The thrombosis rate for subjects who did not receive antithrombin therapy after the diagnosis of HIT was 26.8%, compared to 8.3% for the lepirudin group and 5.9% for the argatroban group (P < 0.01). The incidence of death was also higher in the group of subjects that did not receive antithrombin therapy (48.8%) compared with the lepirudin group (16.7%) or the argatroban group (23.5%), P < 0.01. Conclusion Our findings suggest that thrombin inhibitors can improve the outcomes of patients with HIT by decreasing the incidence of morbidity and mortality relating to HIT. No significant difference could be determined in outcomes between argatroban and lepirudin therapy.

Keywords

Heparin-induced thrombocytopenia Direct thrombin inhibitors 

References

  1. 1.
    Warkentin TE, Greinacher A, Koster A, Lincoff M (2008) Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133:340–380S. doi:10.1378/chest.08-0677 CrossRefGoogle Scholar
  2. 2.
    Chong BH (2003) Heparin-induced thrombocytopenia. J Thromb Haemost 1:1471–1478. doi:10.1046/j.1538-7836.2003.00270.x PubMedCrossRefGoogle Scholar
  3. 3.
    Warkentin TE (2003) Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 121:535–555. doi:10.1046/j.1365-2141.2003.04334.x PubMedCrossRefGoogle Scholar
  4. 4.
    Ahmed I, Majeed A, Poell R (2007) Heparin-induced thrombocytopenia–diagnosis and management update. Postgrad Med J 83:575–582. doi:10.1136/pgmj.2007.059188 PubMedCrossRefGoogle Scholar
  5. 5.
    Efird LE, Kockler DR (2006) Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia. Ann Pharmacother 40:1383–1387. doi:10.1345/aph.1G738 PubMedCrossRefGoogle Scholar
  6. 6.
    Papadopoulos S, Flynn JD, Lewis DA (2007) Fondaparinux as a treatment option for heparin-induced thrombocytopenia. Pharmacotherapy 27:921–926. doi:10.1592/phco.27.6.921 PubMedCrossRefGoogle Scholar
  7. 7.
    Prechel M, Walenga JM (2008) The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update. Semin Thromb Hemost 34:86–96. doi:10.1055/s-2008-1066027 PubMedCrossRefGoogle Scholar
  8. 8.
    Lewis BE, Wallis DE, Berkowitz SD et al (2001) Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 103:1838–1843PubMedGoogle Scholar
  9. 9.
    Clayton SB, Ascell JR, Crumble   et al (2004) Cardiopulmonary bypass with bivalirudin in type II heparin-induced thrombocytopenia. Ann Thorac Surg 78:2167–2169. doi:10.1016/S0003-4975(03)01471-1 PubMedCrossRefGoogle Scholar
  10. 10.
    Finks SW (2006) Bivalirudin use in carotid endarterectomy in a patient with heparin-induced thrombocytopenia. Ann Pharmacother 40:340–343. doi:10.1345/aph.1G307 PubMedCrossRefGoogle Scholar
  11. 11.
    Greinacher A, Volpel H, Janssens U, HIT Investigators Group et al (1999) Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 99:73–80PubMedGoogle Scholar
  12. 12.
    Lo GK, Sigouin CS, Warkentin TE (2007) What is the potential for overdiagnosis of heparin-induced thrombocytopenia? Am J Hematol 82:1037–1043. doi:10.1002/ajh.21032 PubMedCrossRefGoogle Scholar
  13. 13.
    Warkentin TE, Levine MN, Hirsh J et al (1995) Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 335:1330–1335. doi:10.1056/NEJM199505183322003 CrossRefGoogle Scholar
  14. 14.
    Warkentin TE (2004) An overview of the heparin-induced thrombocytopenia syndrome. Semin Thromb Hemost 30:273–283. doi:10.1055/s-2004-831039 PubMedCrossRefGoogle Scholar
  15. 15.
    Warkentin TE, Kelton JG (1996) A 14-year study of heparin-induced thrombocytopenia. Am J Med 101:502–507. doi:10.1016/S0002-9343(96)00258-6 PubMedCrossRefGoogle Scholar
  16. 16.
    Wallis DE, Workman DL, Lewis BE et al (1999) Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 106:629–635. doi:10.1016/S0002-9343(99)00124-2 PubMedCrossRefGoogle Scholar
  17. 17.
    Warkentin TE (2003) Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban. Thromb Res 110:73–82. doi:10.1016/S0049-3848(03)00336-0 PubMedCrossRefGoogle Scholar
  18. 18.
    Greinacher A, Eichler P, Lubenow N et al (2000) Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT rage. Blood 96:846–851PubMedGoogle Scholar
  19. 19.
    Greinacher A, Lubenow N, Eichler P (2003) Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 108:2062–2065. doi:10.1161/01.CIR.0000096056.37269.14 PubMedCrossRefGoogle Scholar
  20. 20.
    Oliviera GB, Crespo EM, Becker RC et al (2008) Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med 168:94–102. doi:10.1001/archinternmed.2007.65 CrossRefGoogle Scholar
  21. 21.
    Altuntas F, Matevosyan K, Burner J et al (2008) Higher optical density of an antigen assay predicts thrombosis in patients with heparin-induced thrombocytopenia. Eur J Haematol 80:429–435. doi:10.1111/j.1600-0609.2008.01035.x PubMedCrossRefGoogle Scholar
  22. 22.
    Zwicker JI, Uhl L, Huang W et al (2004) Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2:2133–2137. doi:10.1111/j.1538-7836.2004.01039.x PubMedCrossRefGoogle Scholar
  23. 23.
    Greinacher A, Juhl D, Strobel U et al (2007) Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 5:1666–1673. doi:10.1111/j.1538-7836.2007.02617.x PubMedCrossRefGoogle Scholar
  24. 24.
    Srinivasan AF, Rice L, Bartholomew JR et al (2004) Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med 164:66–70. doi:10.1001/archinte.164.1.66 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Karen M. Curzio
    • 1
    • 2
  • A. Cheng-Lai
    • 1
  • V. Kheyfets
    • 1
  • M. Sinnet
    • 1
  • H. H. Billett
    • 1
  1. 1.Department of Pharmacy and the Division of Hematology, Department of MedicineMontefiore Medical Center, Albert Einstein College of MedicineBronxUSA
  2. 2.Pharmacy DepartmentGrady Memorial HospitalAtlantaUSA

Personalised recommendations